Goodwin advised Aptinyx on the transaction Aptinyx (“APTX”), a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, closed its public offering of 7,359,998 shares…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
